The aim of the study was to evaluate the feasibility, toxicity and effectiveness of active breathing control-guided stereotactic body radiotherapy in the management of pulmonary oligometastases.
Methods and Study Design
Between June 2010 and June 2012, 20 patients (13 males, 7 females) with 31 pulmonary metastases referred to the Department of Radiation Oncology, Gulhane Military Medical Academy were treated using active breathing control-guided stereotactic body radiotherapy. Response Evaluation Criteria in Solid Tumors and Common Terminology Criteria for Adverse Events were used in the assessment of treatment response and toxicity, respectively.
Results
Assessment of treatment response revealed complete response, partial response, stable disease, and progressive disease in 30%, 25%, 30%, and 15% of the patients, respectively. At a median follow-up of 14 months, local control was 85% and overall survival was 70%, with negligible treatment-related toxicity.
Conclusions
Stereotactic body radiotherapy is safe and effective in the management of pulmonary oligometastases. It offers favorable treatment outcomes as a viable non-invasive therapeutic modality.
SinghD., YiW.S., BrasacchioR.A., MuhsA.G., SmudzinT., WilliamsJ.P., MessingE., OkunieffP.: Is there a favorable subset of patients with prostate cancer who develop oligometastases?Int J Radiat Oncol Biol Phys, 58: 3–10, 2004.
4.
KavanaghB.D., McGarryR.C., TimmermanR.D.: Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases.Semin Radiat Oncol, 16: 77–84, 2006.
5.
YangJ.C., AbadJ., SherryR.: Treatment of oligometastases after successful immunotherapy.Semin Radiat Oncol, 16: 131–135, 2006.
PastorinoU., BuyseM., FriedelG., GinsbergR.J., GirardP., GoldstrawP., JohnstonM., McCormackP., PassH., PutnamJ.B.: Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.J Thorac Cardiovasc Surg, 113: 37–49, 1997.
8.
NagataY., NegoroY., AokiT., MizowakiT., TakayamaK., KokuboM., ArakiN., MitsumoriM., SasaiK., ShibamotoY., KogaS., YanoS., HiraokaM.: Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame.Int J Radiat Oncol Biol Phys, 52: 1041–1046, 2002.
9.
LeeS.W., ChoiE.K., ParkH.J., AhnS.D., KimK.J., YoonS.M., KimY.S., YiB.Y.: Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung.Lung Cancer, 40: 309–315, 2003.
10.
WulfJ., HaedingerU., OppitzU., ThieleW., MuellerG., FlentieM.: Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: A noninvasive treatment approach in medically inoperable patients.Int J Radiat Oncol Biol Phys, 60: 186–196, 2004.
11.
OnishiH., ArakiT., ShiratoH., NagataY., HiraokaM., GomiK., YamashitaT., NiibeY., KarasawaK., HayakawaK., TakaiY., KimuraT., HirokawaY., TakedaA., OuchiA., HareyamaM., KokuboM., HaraR., ItamiJ., YamadaK.: Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study.Cancer, 101: 1623–1631, 2004.
12.
NagataY., TakayamaK., MatsuoY., NorihisaY., MizowakiT., SakamotoT., SakamotoM., MitsumoriM., ShibuyaK., ArakiN., YanoS., HiraokaM.: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.Int J Radiat Oncol Biol Phys, 63: 1427–1431, 2005.
SagerO., BeyzadeogluM., DincoglanF., OysulK., KahyaY.E., GamsizH., UysalB., DemiralS., DiricanB., SurenkokS.: Evaluation of active breathing control-moderate deep inspiration breath-hold in definitive non-small cell lung cancer radiotherapy.Neoplasma, 59: 333–340, 2012.
15.
SagerO., BeyzadeogluM., DincoglanF., OysulK., KahyaY.E., GamsizH., UysalB., DemiralS., DiricanB., SurenkokS.: The role of active breathing control-moderate deep inspiration breath-hold (ABC-mDIBH) usage in non-mastectomized left-sided breast cancer radiotherapy: a dosimetric evaluation.UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 22: 147–155, 2012.
16.
DincoglanF., BeyzadeogluM., SagerO., OysulK., KahyaY.E., GamsizH., UysalB., DemiralS., DiricanB., SurenkokS.: Dosimetric evaluation of critical organs at risk in mastectomized left-sided breast cancer radiotherapy using breath-hold technique.Tumori, 99: 76–82, 2013.
17.
ScorsettiM., MancosuP., NavarriaP., TozziA., CastiglioniS., ClericiE., ReggioriG., LobefaloF., FogliataA., CozziL.: Stereotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of advanced techniques with modulated photons and protons.Strahlenther Onkol, 187: 238–244, 2011.
18.
HolyR., PirothM., PinkawaM., EbleM.J.: Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer.Strahlenther Onkol, 187: 245–251, 2011.
19.
ZamboglouC., MessmerM.B., BeckerG., MommF.: Stereotactic radiotherapy in the liver hilum. Basis for future studies.Strahlenther Onkol, 188: 35–41, 2012.
20.
Duncker-BohrV., NestleU., MommF., ProkicV., HeinemannF., MixM., ReuschJ., MessmerM.B., MarschnerN., WallerC.F., WeberW.A., GrosuA.L.: Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity.Strahlenther Onkol, 189: 33–40, 2013.
YoonS.M., ChoiE.K., LeeS.W., YiB.Y., AhnS.D., ShinS.S., ParkH.J., KimS.S., ParkJ.H., SongS.Y., ParkC.I., KimJ.H.: Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors.Acta Oncol, 45: 1108–1114, 2006.
23.
MilanoM.T., KatzA.W., MuhsA.G., PhilipA., BuchholzD.J., SchellM.C., OkunieffP.: A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions.Cancer, 112: 650–658, 2008.
24.
MilanoM.T., KatzA.W., SchellM.C., PhilipA., OkunieffP.: Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy.Int J Radiat Oncol Biol Phys, 72: 1516–1522, 2008.
